Literature DB >> 21724443

Treatment adherence in patients with gout.

Gérard Reach1.   

Abstract

The treatment objectives in gout are to promptly terminate the acute flares and to prevent the long-term complications via chronic pharmacotherapy, usually with urate-lowering drugs, combined with diet and lifestyle changes. Published data indicate that adherence with pharmacotherapy is particularly poor in gout patients. In studies of pharmacy dispensing of gout medications, the percentage of patients with good adherence, defined as purchasing at least 80% of the prescribed amount of medication, ranged from 18 to 44%. In a comparative study showing a 36.8% adherence rate among gout patients, patients with hypertension or type 2 diabetes had considerably higher rates, of 72.3 and 65.4%, respectively. In addition, data are lacking on adherence to recommended dietary and lifestyle changes, whose importance has been emphasized in recent years. Poor adherence has well-documented adverse consequences on the treatment success rate and on disease progression. These data identify treatment adherence in gout as a key target of patient education.
Copyright © 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21724443     DOI: 10.1016/j.jbspin.2011.05.010

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  23 in total

1.  Crystal arthritis: a new 'package of care' strategy for effective gout management.

Authors:  Nicola Dalbeth
Journal:  Nat Rev Rheumatol       Date:  2012-07-31       Impact factor: 20.543

Review 2.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

3.  Poorly controlled gout: who is doing poorly?

Authors:  Faith Li-Ann Chia
Journal:  Singapore Med J       Date:  2016-08       Impact factor: 1.858

4.  Allopurinol use in a New Zealand population: prevalence and adherence.

Authors:  Simon Horsburgh; Pauline Norris; Gordon Becket; Bruce Arroll; Peter Crampton; Jacqueline Cumming; Shirley Keown; Peter Herbison
Journal:  Rheumatol Int       Date:  2014-01-04       Impact factor: 2.631

Review 5.  The patient's experience of gout: new insights to optimize management.

Authors:  Nicola Dalbeth; Karen Lindsay
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

6.  A qualitative and quantitative analysis of the characteristics of gout patient education resources.

Authors:  Philip C Robinson; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-01-16       Impact factor: 2.980

7.  Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Authors:  Nicola Dalbeth; Meaghan E House; Anne Horne; Keith J Petrie; Fiona M McQueen; William J Taylor
Journal:  BMC Musculoskelet Disord       Date:  2012-09-16       Impact factor: 2.362

8.  Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.

Authors:  Kowoon Joo; Seong-Ryul Kwon; Mie-Jin Lim; Kyong-Hee Jung; Hoyeon Joo; Won Park
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

Review 9.  A patient-centered gout information value chain: a scoping review.

Authors:  Maranda J Russell; Sujin Kim; Aleksander Lenert
Journal:  Patient Educ Couns       Date:  2021-06-08

Review 10.  The emerging role of biotechnological drugs in the treatment of gout.

Authors:  L Cavagna; W J Taylor
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.